These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21795246)

  • 1. Chronic kidney disease-mineral bone disorder (CKD-MBD) management and associated cost in an Irish haemodialysis cohort.
    Ward F; Watson A; Holian J
    Nephrol Dial Transplant; 2011 Oct; 26(10):3417. PubMed ID: 21795246
    [No Abstract]   [Full Text] [Related]  

  • 2. [CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder].
    Mizobuchi M; Aoshima Y; Akizawa T
    Clin Calcium; 2010 Jul; 20(7):995-1003. PubMed ID: 20585177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal artery occlusion in autosomal dominant polycystic kidney disease.
    Sánchez M; Enríquez R; Sirvent AE; Millan I; de la Iglesia P; Amorós F
    Ren Fail; 2014 Aug; 36(7):1142-4. PubMed ID: 24827072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autosomal dominant polycystic kidney disease and the heart and brain.
    Krishnappa V; Vinod P; Deverakonda D; Raina R
    Cleve Clin J Med; 2017 Jun; 84(6):471-481. PubMed ID: 28628430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Gabow PA
    Kidney Int Suppl; 1997 Oct; 61():S71-3. PubMed ID: 9328971
    [No Abstract]   [Full Text] [Related]  

  • 8. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
    McCarthy S; McMullen M
    ANNA J; 1997 Feb; 24(1):45-51; quiz 52-3. PubMed ID: 9146123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).
    Moe SM; Seifert MF; Chen NX; Sinders RM; Chen X; Duan D; Henley C; Martin D; Gattone VH
    Nephrol Dial Transplant; 2009 Aug; 24(8):2371-7. PubMed ID: 19258382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Extra-renal manifestations of the autosomal dominant polycystic kidney disease].
    Butscher A; Phan O; Bonny O
    Rev Med Suisse; 2017 Feb; 13(551):450-456. PubMed ID: 28714645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension, lipid abnormalities and cardiovascular changes in autosomal dominant polycystic kidney disease.
    Polat H; Karayaylali I; Niyazova Z; Seyrek N; Paydaş S; Sagliker Y
    Nephron; 1998; 78(3):369-71. PubMed ID: 9546713
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease.
    Haseebuddin M; Tanagho YS; Millar M; Roytman T; Chen C; Clayman RV; Miller B; Desai A; Benway B; Bhayani S; Figenshau RS
    J Urol; 2012 Oct; 188(4):1239-44. PubMed ID: 22902029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrarenal manifestations of autosomal dominant polycystic kidney disease.
    Pirson Y
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):173-80. PubMed ID: 20219620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F; Maruta Y
    Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?
    Jankowska M; Qureshi AR; Barany P; Heimburger O; Stenvinkel P; Lindholm B
    Nephrology (Carlton); 2018 Jan; 23(1):31-36. PubMed ID: 27653449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic kidney disease presenting with hypertension and hypokalemia.
    Chow KM; Ma RC; Szeto CC; Li PK
    Am J Kidney Dis; 2012 Feb; 59(2):270-2. PubMed ID: 21962616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.
    van Gulick JJ; Gevers TJ; van Keimpema L; Drenth JP
    Neth J Med; 2011 Sep; 69(9):367-71. PubMed ID: 21978978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2016 May; 67(5):792-810. PubMed ID: 26530876
    [No Abstract]   [Full Text] [Related]  

  • 19. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years.
    Dicks E; Ravani P; Langman D; Davidson WS; Pei Y; Parfrey PS
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):710-7. PubMed ID: 17699277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension in ADPKD.
    Watson ML; Macnicol AM; Wa TC
    Contrib Nephrol; 1995; 115():59-64. PubMed ID: 8585920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.